Published in Women's Health Weekly, February 12th, 2009
“This study shows that treating uterine fibroids with MRgFUS is a cost-effective option for payers” said David Lee Ph.D., Senior Director, Health Economics and Outcomes Research, GE Healthcare. “With any healthcare treatment, there is the direct cost of the procedure, but there’s also the indirect cost of lost...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly